HOME
COMPANY
About us
Vision
Mission
History
Team
SCIENCE & RESEARCH
New target
Oncology
Infectious diseases
Research collaborations
Clinical trial capabilities
Our pipeline
Science & research
Expanded Access
TECHNOLOGIES
Process science
Expression system
Process development
GMP manufacturing
Quality Control
Quality Management
CDMO
Business opportunities
NEWS & EVENTS
NEWS & EVENTS
Meet us
CAREER
Working with us
Job vacancies
CONTACT US
Location
Contact
EN
CN
NEWS AND EVENTS
Meplazumab was approved for phase II/III clinical trials for the treatment of COVID-19 pneumonia by US FDA on November 13, 2020.
November 13,2020
Meplazumab was approved for phase I/II clinical trial for the treatment of COVID-19 pneumonia by China NMPA on March 28, 2020.
March 28,2020
US FDA designated as a Fast Track development program the investigation of Meplazumab for Injection for the treatment and prophylaxis of malaria on February 15, 2020.
February 15,2020
PMBP had a successful Pre-IND meeting for Meplazumab for acute and preventive treatment of malaria with the US FDA on August 15, 2019.
August 15,2019
PMBP's orphan-drug designation request of Meplazumab was granted for treatment of malaria by US FDA on March 15, 2019.
March 15,2019
TOTAL5/1PAGE
<<
<
1
>
>>
COMPANY
About us
Vision
Mission
History
Team
News and events
News and events
Meet us
SCIENCE & RESEARCH
New target
Oncology
Infectious diseases
Research collaborations
Clinical trial capabilities
Our pipeline
Science & research
Expanded Access
CAREER
Working with us
Job vacancies
TECHNOLOGIES
Process science
Expression system
Process development
GMP manufacturing
Quality Control
Quality Management
CDMO
Business opportunities
CONTACT US
Location
Contact
Stay up to date on Pacific Meinuoke
© Pacific Meinuoke
Legal Notice
苏ICP备10218680号-1
